Divalproex sodium (Depakote ER)
Small molecule
Evidence outlook
Approved: Migraine, Epilepsy, Bipolar Disorder, Absence Seizures, Focal Onset Seizures
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
Latest reported trial: NCT00060905 · Phase 3 · met primary endpoint · grade pending
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT00060905 NCT00060905 · Bipolar Disorder Registry: NCT00060905 | 3 | Change from baseline to the final evaluation for the MRS from the SADS-C for the intent-to-treat dataset. | Mania Rating Scale improvement was significantly greater with divalproex ER than placebo from day 5 through day 21 (p = .013). | not yet graded | link ↗ |
View 1 more trial
NCT00195780 NCT00195780 · Bipolar I Disorder Registry: NCT00195780 | 3 | Safety | In the open-label safety study 226 youths enrolled and 109 completed; the commonest adverse events were weight gain (16%), nausea (9%) and increased appetite (8%). | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (8)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (3)
What this study did
What this study did
What this study did
Phase 1 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (9)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Early phase / not applicable (1)
What this study did
Used as active comparator (2)
Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.
Phase 1 (2)
What this study did
What this study did
Competitive landscape
Other GABAergic neurotransmission drugs
Divalproex sodium (Depakote), valproate. Compare all 3 GABAergic neurotransmission drugs
2 other tracked programmes target this mechanism, none of them ahead of this one.
This drug's own stage for Absence Seizures: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Divalproex Sodium (Depakote ER): this drug | Approved | Small molecule | GABAergic neurotransmission | not yet graded | No reviewed efficacy summary in this indication | |
| Divalproex Sodium (Depakote) | Approved | Small molecule | GABAergic neurotransmission | not yet graded | No reviewed efficacy summary in this indication | |
| Valproate | ApprovedUS marketing discontinued | Small molecule | GABAergic neurotransmission | not yet graded | No reviewed efficacy summary in this indication | |
| BMB-101 | Phase 2 | Small molecule | Serotonin 5-HT2C receptor (biased agonist) | not yet graded | No reviewed efficacy summary in this indication |
Compare side by side
Upcoming events
No upcoming readouts on record for this asset.